"Tegafur" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.
| Descriptor ID |
D005641
|
| MeSH Number(s) |
D03.383.742.698.875.404.850
|
| Concept/Terms |
Tegafur- Tegafur
- 1-(Tetrahydro-2-furanyl)-5-fluorouracil
- N1-(2'-Tetrahydrofuryl)-5-fluorouracil
- 1-(2-Tetrahydrofuryl)-5-fluorouracil
- 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione
|
Below are MeSH descriptors whose meaning is more general than "Tegafur".
Below are MeSH descriptors whose meaning is more specific than "Tegafur".
This graph shows the total number of publications written about "Tegafur" by people in this website by year, and whether "Tegafur" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 4 | 4 |
| 2001 | 2 | 0 | 2 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 3 | 3 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tegafur" by people in Profiles.
-
Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Radiat Oncol. 2019 Mar 27; 14(1):52.
-
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017 Sep 01; 28(9):2142-2148.
-
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). J Gastrointest Cancer. 2015 Jun; 46(2):109-17.
-
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer. 2013 Nov; 49(17):3616-24.
-
A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol. 2011 Jun; 7(6):715-26.
-
A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer. 2010 May 15; 116(10):2301-6.
-
A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer. 2010 Mar 15; 116(6):1440-5.
-
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010 Mar 20; 28(9):1547-53.
-
A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer. 2008 Sep 02; 99(5):722-6.
-
Medical treatment for advanced gastroesophageal adenocarcinoma. Curr Opin Gastroenterol. 2007 Nov; 23(6):631-5.